Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Down 5.6 %

NASDAQ:ADXS opened at $0.54 on Wednesday. Ayala Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.95. The stock has a 50-day moving average price of $0.70 and a 200 day moving average price of $0.74. The stock has a market capitalization of $5.81 million, a P/E ratio of -0.07 and a beta of 1.62.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.